Use of Nonsteroidal Anti-Inflammatory Drugs and Risk of Breast Cancer: Evidence from a General Female Population and a Mammographic Screening Cohort in Sweden.

Hu K, Feychting M, Lu D, Sjölander A, Czene K, Hall P, Fang F.

Cancer (Basel)


Prospective validation of the BOADICEA multifactorial breast cancer risk prediction model in a large prospective cohort study.

Yang X, Eriksson M, Czene K, Lee A, Leslie G, Lush M, Wang J, Dennis J, Dorling L, Carvalho S, Mavaddat N, Simard J, Schmidt MK, Easton DF, Hall P, Antoniou AC.

J Med Genet

Postmenopausal overweight and breast cancer risk; results from the KARMA cohort.

Klintman M, Rosendahl AH, Randeris B, Eriksson M, Czene K, Hall P, Borgquist S.

Breast Cancer Res Treat

Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial

Magnus Bäcklund, Mikael Eriksson, Marike Gabrielson, Mattias Hammarström, Steve Quay, Jenny Bergqvist, Roxanna Hellgren, Kamila Czene, Per Hall.


Risk Assessment in Population-Based Breast Cancer Screening.

Eriksson M, Conant EF, Kontos D, Hall P.


Time to Mammographic Density Decrease After Exposure to Tamoxifen

Magnus Bäcklund, Mikael Eriksson, Mattias Hammarström, Linda Thoren, Jenny Bergqvist, Sara Margolin, Roxanna Hellgren, Yvonne Wengström, Marike Gabrielson, Kamila Czene, Per Hall.


Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention.

Moorthie S, Babb de Villiers C, Burton H, Kroese M, Antoniou AC, Bhattacharjee P, Garcia-Closas M, Hall P, Schmidt MK.

Prev Med

A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care.

Eriksson M, Destounis S, Czene K, Zeiberg A, Day R, Conant EF, Schilling K, Hall P.

Sci Transl Med

Estimating Distributions of Breast Cancer Onset and Growth in a Swedish Mammography Screening Cohort.

Strandberg R, Czene K, Eriksson M, Hall P, Humphreys K.

Cancer Epidemiol Biomarkers

Risk of heart disease following treatment for breast cancer – results from a population-based cohort study.

Yang H, Bhoo-Pathy N, Brand JS, Hedayati E, Grassmann F, Zeng E, Bergh J, Bian W, Ludvigsson JF, Hall P, Czene K.


Interval breast cancer is associated with interferon immune response.

Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Lindström LS, Vallon-Christersson J, Borg Å, Hall P, Czene K.

Eur J Cancer

Circulating proteins reveal prior use of menopausal hormonal therapy and increased risk of breast cancer.

Thomas CE, Dahl L, Byström S, Chen Y, Uhlén M, Mälarstig A, Czene K, Hall P, Schwenk JM, Gabrielson M.

Transl Oncol


[It is time for individual breast cancer prevention].

Hall P, Hammarström M, Hellgren R.


Mammographic features are associated with cardiometabolic disease risk and mortality.

Grassmann F, Yang H, Eriksson M, Azam S, Hall P, Czene K.

Eur Heart J

Mammographic microcalcifications and risk of breast cancer.

Azam S, Eriksson M, Sjölander A, Gabrielson M, Hellgren R, Czene K, Hall P.

Br J Cancer

CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial

W He, M Eriksson, E Eliasson, F Grassmann, M Bäcklund, M Gabrielson, M Hammarström, S Margolin, L Thorén, Y Wengström, S Borgquist, P Hall, K Czene.

Annals of Oncology

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.

Eriksson M, Eklund M, Borgquist S, Hellgren R, Margolin S, Thoren L, Rosendahl A, Lång K, Tapia J, Bäcklund M, Discacciati A, Crippa A, Gabrielson M, Hammarström M, Wengström Y, Czene K, Hall P.

J Clin Oncol.

Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.

Ong JS, Derks EM, Eriksson M, An J, Hwang LD, Easton DF, Pharoah PP, Berchuck A, Kelemen LE, Matsuo K, Chenevix-Trench G, Hall P, Bojesen SE, Webb PM, MacGregor S.

Int J Cancer

Breast Cancer Risk Genes – Association Analysis in More than 113,000 Women.

Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, et al.

N Engl J Med.

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women.

Eriksson M, Czene K, Conant EF, Hall P.

Cancers (Basel).